Int J Biol Sci 2016; 12(3):270-272. doi:10.7150/ijbs.14950
Pancreatic Cancer: Current Progress and Future Challenges
Head Pancreatic Cancer Unit, Laboratory of Human Carcinogenesis, Center for Cancer Research, National Cancer Institutes, NIH, Bethesda, MD 20892, USA
Pancreatic ductal adenocarcinoma (PDAC), the most common form of pancreatic cancer, remains one of the highly lethal malignancies. The highly refractory nature of clinically advanced disease and lack of a reliable biomarker for early detection are major obstructions in improving patient outcome. The recent efforts, however, in understanding the pancreatic tumor biology have resulted in the recognition of novel addictions as well as vulnerabilities of tumor cells and are being assessed for their clinical potential. This special issue highlights some of the recent progress, complexity and challenges towards improving disease outcome in patients with this lethal malignancy.
Keywords: Pancreatic Cancer
This is an open access article distributed under the terms of the Creative Commons Attribution (CC BY-NC) License. See http://ivyspring.com/terms for full terms and conditions.
How to cite this article:
Hussain SP. Pancreatic Cancer: Current Progress and Future Challenges. Int J Biol Sci 2016; 12(3):270-272. doi:10.7150/ijbs.14950. Available from http://www.ijbs.com/v12p0270.htm